ASCO Annual Meeting

This roundup includes exclusive insights from nearly 20 clinicians and key data on the top abstracts coming out of the 2024 ASCO Annual Meeting.

Patients with leptomeningeal metastasis from HER2-positive breast cancer experienced clinical benefit with tucatinib plus trastuzumab and capecitabine.

Talquetamab proved safe and effective for relapsed/refractory myeloma, even in patients with comorbidities.

Clinical benefit generated from treatment with lurbinectedin plus irinotecan was noted across sensitive and resistant patient populations with SCLC.

Axi-cel administration was safe and clinically active in relapsed/refractory primary and secondary central nervous system lymphoma.

The strength of mKRAS-specific T-cell responses produced by ELI-002 7P correlated with tumor biomarker responses in pancreatic and colorectal cancer.

A novel radioligand therapy, JNJ-6420, demonstrates potential in treating mCRPCr, delivering sustained responses following only 1-2 doses.

The investigational PROTAC AR degrader ARV-766 showed promising clinical activity and tolerability in patients with metastatic castration-resistant prostate cancer.

MammaPrint high 2 HR-positive/HER2-negative early-stage breast cancer exhibited a heightened immune active state.

Linvoseltamab elicited outcomes equivalent to those seen with teclistamab in patients with triple-class exposed relapsed/refractory multiple myeloma.

Dostarlimab plus carboplatin and paclitaxel improved PFS and OS in dMMR/MSI-H primary advanced or recurrent endometrial cancer.

Pembrolizumab and platinum-based therapy elicited safe and efficacious outcomes in penile squamous cell carcinoma.

Partition overall survival data indicated that nivolumab plus cabozantinib extended treatment-free survival vs sunitinib in advanced renal cell carcinoma.

Cretostimogene grenadenorepvec plus pembrolizumab sustains high CR rate in NMIBC according to the phase 2 CORE-001 trial.

Apalutamide/ADT maintains quality of life, demonstrates improved PSA progression-free survival in recurrent prostate cancer according to PRESTO trial.

Trastuzumab deruxtecan improved responses and survival vs T-DM1 in HER2+ metastatic breast cancer after prior exposure to trastuzumab and a taxane.

Retreatment with daratumumab-based regimens led to a similar ORR vs initial daratumumab treatment in relapsed/refractory myeloma.

Treatment cessation of enzalutamide-containing regimens in responding patients had no impact on QOL in biochemically recurrent nmHSPC.

Ana Christina Garrido-Castro, MD, on sacituzumab govitecan with/without pembrolizumab in metastatic hormone receptor–positive, HER2-negative breast cancer.

Olverembatinib showed antitumor activity in patients with TKI-resistant, SDH-deficient GISTs and paraganglioma.

TTFields therapy plus best supportive care increased time to first intracranial progression by 10.6 months in patients with NSCLC brain metastases.

Jennifer R. Eads, MD, discusses neoadjuvant pCR rates with the addition of nivolumab to neoadjuvant chemoradiation in esophageal/GEJ cancer.

Jean-Marc Classe, MD, PhD, discusses lymphadenectomy omission following cytoreductive surgery after chemotherapy in advanced epithelial ovarian cancer.

Petosemtamab paired with pembrolizumab had early clinical efficacy when used as first-line treatment in select head and neck squamous cell carcinoma

Nivolumab plus ipilimumab and chemotherapy elicited a durable, long-term survival benefit vs chemotherapy alone in metastatic NSCLC.

Bradley McGregor, MD, discusses the DAD-IO trial of sacituzumab govitecan, enfortumab vedotin, and pembrolizumab in metastatic urothelial cancer.

Daratumumab plus VRd increased rates of MRD negativity in newly diagnosed, transplant-eligible multiple myeloma.

The addition of avelumab to cisplatin-based chemotherapy led to high event-free survival and overall survival rates in patients with muscle-invasive urothelial carcinoma.

Isatuximab plus VRd produced a statistically significant improvement in PFS vs VRd in newly diagnosed, transplant-ineligible multiple myeloma.

In a phase 2 trial, all 42 patients with locally advanced mismatch repair–deficient rectal cancer achieved clinical complete response with dostarlimab.